Close

Celgene Corp (CELG) Tops Q1 EPS by 2c

April 24, 2014 7:35 AM EDT

Celgene Corp (NASDAQ: CELG) reported Q1 EPS of $1.67, $0.02 better than the analyst estimate of $1.65. Revenue for the quarter came in at $1.71 billion versus the consensus estimate of $1.77 billion.

Net Product Sales Performance

  • REVLIMID® sales for the first quarter increased 14 percent to $1,144 million and were driven by overall market share, increased duration of therapy and geographic expansion. U.S. sales of $642 million and International sales of $502 million increased 13 percent and 16 percent, respectively.
  • ABRAXANE® sales for the first quarter were $185 million, a 51 percent increase. U.S. sales of $142 million and International sales of $43 million increased 51 percent and 49 percent, respectively. The increase in sales reflects the impact of the ongoing U.S. launch in pancreatic cancer and early launch success for pancreatic cancer in Europe.
  • VIDAZA® first quarter sales decreased 27 percent to $148 million. U.S. sales decreased 83 percent to $14 million reflecting the impact of a full quarter of generic competition. International sales were $134 million and increased 14 percent from 2013. International sales were driven by increased demand in Europe and Japan.
  • POMALYST®/IMNOVID® sales were $136 million. U.S. sales were $89 million and International sales were $47 million. POMALYST®/IMNOVID® sales were driven by market share gains and increasing duration in the U.S. and the commercial launch in Europe.
  • All other product sales, which include THALOMID®, ISTODAX® and an authorized generic of VIDAZA® drug product in the U.S., were $95 million in the first quarter of 2014 compared to $71 million for the first quarter of 2013.

Celgene Corp reaffirmed FY2014 guidance.

For earnings history and earnings-related data on Celgene Corp (CELG) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, FDA, Hot Earnings

Related Entities

Earnings